Harmony Biosciences Holdings, Inc. (HRMY)
$52
+3.23 (+6.62%)
Rating:
Recommendation:
-
| Symbol | HRMY |
|---|---|
| Price | $52 |
| Beta | 0.000 |
| Volume Avg. | 0.52M |
| Market Cap | 3.071B |
| Shares () | - |
| 52 Week Range | 25.09-54.0 |
| 1y Target Est | - |
| DCF Unlevered | HRMY DCF -> | |
|---|---|---|
| DCF Levered | HRMY LDCF -> | |
| ROE | 28.66% | Buy |
| ROA | 10.49% | Buy |
| Operating Margin | - | |
| Debt / Equity | 116.32% | Buy |
| P/E | 65 | Strong Buy |
| P/B | 14.28 | Strong Buy |
Latest HRMY news
About
Download (Excel)Mr. John Charles Jacobs M.B.A.
Healthcare
Biotechnology
NASDAQ Global Market
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.